The MART-1/Melan-A recognizes a protein of 18 kDa, identified as MART-1 antibody (Melanoma Antigen Recognized by T cells 1) or Melan-A. MART-1 antibody recognizes a subcellular fraction found in melanosomes. The antibody labels melanomas and tumors showing melanocytic differentiation. It does not mark neoplasms of epithelial origin, lymphomas or mesenchymal tumors. MART-1 is a useful addition to melanoma panels which are specific to melanocytic lesions. MART-1 is coexpressed with HMB45 in the majority of melanomas, as well as solely expressed in certain cases. Studies have shown that MART-1 is more sensitive than HMB45 when labeling metastatic melanomas.
|Download Data Sheet
|Download RUO Data Sheet for International
|Download SDS Sheet
Regulatory Notice: Biocare’s IVD-labeled products comply with US-FDA and European IVDD regulation. Other regions may have additional requirements for such labeling, please contact your local distributor.
1. Orchard GE. Melan A (MART-1): a new monoclonal antibody for malignant
melanoma diagnosis. Br J Biomed Sci 1998 Mar; 55(1):9-9.
2. Blessing K, Sanders DS, Grant JJ. Comparison of immunohistochemical staining of
the novel antibody Melan-A with S100 protein and HMB-45 in malignant melanoma
and melanoma variants. Histopathology 1998 Feb; 32(2):139-146.
3. Kageshita T, et al. Differential expression of MART-1 in primary and metastatic
melanoma lesions. J Immunother 1997 Nov; 20(6):460-465.
4. Center for Disease Control Manual. Guide: Safety Management, NO. CDC-22,
Atlanta, GA. April 30, 1976 “Decontamination of Laboratory Sink Drains to Remove
5. Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory
workers from occupationally Acquired Infections; Approved guideline-Third Edition
CLSI document M29-A3 Wayne, PA 2005.